Collection of RECENT BUYS (January 2017 Summary)

Since our family began investing in dividend stocks approximately two and a half years ago, I've been keeping a personal log of what other dividend bloggers and dividend investors are buying. The collection essentially highlights the Recent Buys that I discover throughout the dividend blog community. Its nice to see what others are buying, if for nothing more to get some ideas.  

This collection started out as my own personal data sheet but I have since decided to share it with the DGI community.  I am glad I did because, as evident in our recent post (We Just Joined the 400K club), it has been once of the more popular pages on our blog!! We hope it everyone continues to use our Collection of Recent Buys and it remains a great resource for all. It can be a lot of work to maintain but we remain committed and will do our best to keep this list up to date. 

Please feel free to bookmark or share the page: 

 COLLECTION OF RECENT BUYS

AND NOW FOR THE SUMMARY OF
WHAT EVERYONE HAS BEEN BUYING THIS PAST MONTH

During the month of January a total of 49 buys were found throughout the DGI community. Given that the DOW is now above the 20,000 threshold, and there is much uncertainty of what Donald Trump's next move is, it appears that buying activities have slowed a bit.  

Below is a chart and corresponding table that identifies those companies that were purchased three or more times this past month: 

To summarize the past month, out of a total of 49 buys found around the DGI community (with a minimum total of $300), a total of 31 companies were purchased with a total of only 8 companies that were bought more than once. From the buys collected,  DGI investors picked up a stock not purchased by others 63% of the time. 

For the month of January, V.F. Corporation (VFC) lead the charge as the most popular stocks among DGI investors this past month. UL was purchased by 5 different investors throughout the DGI community. Our family also managed to grab a few shares of this popular choice among DGI investors. On January 26, 2017, our family picked up 8 shares of V.F. Corporation (VFC) at $52.00.

The second most popular stock this past month was Unilever (UL) which was purchased by 4 different investors throughout the DGI community.  UL appears to have remained on everybody's radar since November, when it was the most bought stock in the DGI community.

Rounding up the third was a 4-way tie between Gilead Sciences, Inc (GILD), Procter & Gamble (PG), Target Corporation (TGT), and CVS Pharmacy (CVS). All four companies were purchased by 3 difference investors throughout the DGI community. Our family grabbed 7 shares of Gilead Sciences (GILD) at $71.33 on January 19, 2017. 

Although not included in the above summary charts, it is worth mentioning that the following two stocks were bought more than once this past month:   

1. AbbVie Inc (ABBV)
2. Qualcomm Inc (QCOM)

Data used for this SUMMARY is from our 

 COLLECTION OF RECENT BUYS

What have you been buying?  Please feel free to share in the comments or send me a link to your Recent Buy post in case I happened to have missed it.

If you have a chance, make sure you also take a look at my COLLECTION OF STOCK ANALYSES!! As with my collection of recent buys, my goal is to make this collection also become a centralized source for everyone. It could become a place where one can get ideas on what to invest in next, to establish a desired stock purchase price, or simply to see what your favorite blogger is buying.  Whatever your reason, my hope is that this collection proves to be a great reference tool and helps provide you that little extra advantage that you are looking for in order to succeed with your investing.

Also, if you have a chance, make sure you also follow or visit Adam over at I Want to Retire Soon (IWTRS) as he generally provides a weekly summary of recent buys! A link to past summaries is maintained on his blog. Another great resource for ideas if you are not sure where to invest next! 

RECENT BUY : Gilead Sciences Inc (NYSE: GILD)

We Recently Purchased The Following:

Gilead Sciences Inc (GILD)

Purchased 7 shares of GILD on 1/19/2017 at $71.33
Total Spent: $499.31; added $13.16 in forward dividends.

We currently own shares of Gilead Sciences Inc (GILD) our family's dividend stocks portfolio. We initially purchased shares in GILD back on 9/9/2016 when we picked up 8 shares at $78.53. But with the current price near the 52-week low, we decided to add a few more shares of GILD to our family's dividend stocks portfolio. With our recent purchase, we now own 15 shares of GILD and have lowered our cost basis from $78.53 to $75.17. We also now receive $28.20 a year in dividends from GILD! 

Based on our research, and the numerous articles relating to GILD, we find that GILD is a great value at current prices and a stock we certainly don't mind holding in our dividend stocks portfolio. Below are just a few links to Seeking Alpha articles on GILD:

1. GILD is a core holding for 2017 - Trey Henninger
2. Why Gilead is undervalued - Truth Investor
3. How will Glead far in 2017 - Jonathon Weber
4. Gilead is a fantastic stock to own at this price - Michael Wiggins De Oliveira
5. Cure your portolio with Gilead - Blue Chip Investing
6. Don't Trust Gilead's P/E Ratio - Erick Kobayashi-Solomon

Company Description

From Google Finance:

“Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.”

With our recent purchase of Gilead Sciences Inc (GILD), the estimated forward dividends for our family's dividend stocks portfolio grew another $13.16, putting our yearly dividends at approximately $2,831/year (excluding our Edwards Jones account) and $3,242/year (including our Edward Jones account).  

Since we already own Gilead Sciences Inc (GILD), the total stocks held in our  dividend stocks portfolios (WF and EJ Accounts) remains at 59 different dividend paying stocks/ETFs and also 5 companies that either don't pay a dividend our has currently suspended their dividends.

Our family's dividend stocks portfolio may be found

by clicking on the link below:

DIVIDEND STOCKS PORTFOLIO

We also maintain an extensive list of stock analysis

that can be access through the link below:

COLLECTION OF STOCK ANALYSES

We also just started a list of Recent Buys by other bloggers

that can be access through the link below:

COLLECTION OF RECENT BUYS

HERE IS A QUICK FACT SHEET FOR THE STOCK I JUST PURCHASED:

Gilead Sciences Inc (GILD)

P/E: 6.59

Payout Ratio: 16%
Dividend Yield: 2.64%
1 consecutive years of dividend increases
Last Ex-dividend date: 12/13/2016

Next Ex-dividend date: approx. 3/13/2017
Have paid a dividend since: 2015 (1 year)
Pays a dividend 4 times a year
Market Cap: 93.88 Billion
52-week high: $103.10
52-week low: $69.78
Purchased Price: $71.33

What are your thoughts on of recent purchase?

What are you buying?

RECENT BUY : (NYSE: GILD)

We Recently Purchased The Following:

Gilead Science, Inc (GILD)

Purchased 8 shares of GILD on 9/9/2016 at $78.53
Total Spent: $628.24; added $15.04 in forward dividends.

Our recent purchase of Gilead Science, Inc (GILD) is just the 3rd stock purchase made in our family's dividend stocks portfolio since February. We also bought Apple Inc (AAPL) and Flower Foods Inc (FLO), on June 24, 2016 and September 9, 2016, respectively. We hope the market continues to decline (as it did on Friday) so that we can continue grabbing a few more value buys! Not sure about you, but whether it is a stock or a consumer good, I love it when I can grab a good deal!  

Here are a few reasons why we believe GILD is a good buy: 1) GILD is trading at a 31.5% discount from its 52-week high; 2) Although the dividend is only 2.41%, their payout ratio is a low 16.4% which should allow GILD to continue to raise dividends for years to come; 3) GILD is a very large company with a market cap at 103.0 Billion.

Company Description

From Google Finance:

“Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.”

With our recent purchase of Gilead Science, Inc (GILD), the estimated forward dividends for our family's dividend stocks portfolio grew another $15.04, putting our yearly dividends at approximately $3,289/year (excluding our Edwards Jones account) and $3,674/year (including our Edward Jones account).  

Since did not previously own Gilead Science Inc, the recent buy of GILD added yet another dividend paying company to our family's dividend stocks portfolios (WF and EJ Accounts). The total stocks held in our family's dividend stock portfolio is now 56 different dividend paying stocks/ETFs and also 5 companies that either don't pay a dividend our has currently suspended their dividends.

Our family's dividend stocks portfolio may be found

by clicking on the link below:

DIVIDEND STOCKS PORTFOLIO

We also maintain an extensive list of stock analysis

that can be access through the link below:

COLLECTION OF STOCK ANALYSES

We also just started a list of Recent Buys by other bloggers

that can be access through the link below:

COLLECTION OF RECENT BUYS

HERE IS A QUICK FACT SHEET FOR THE STOCK I JUST PURCHASED:

Gilead Science, Inc (GILD)

P/E: 6.88

Payout Ratio: 16.4%
Dividend Yield:2.41%
1 consecutive years of dividend increases
Last Ex-dividend date: 6/14/2016

Next Ex-dividend date: approx. 9/14/2016
Have paid a dividend since: 2015 (1 year)
Pays a dividend 4 times a year
Market Cap: 103.0 Billion
52-week high: $113.31
52-week low: $76.67
Purchased Price: $78.53

What are your thoughts on of recent purchase?

What are you buying?